BASF PHARMA (German group BASF) is to sell its European generic medicines business to the Austrian subsidiary of Swiss NOVARTIS, specialised in this field, for the sum of EUR 115 million, as of 1 January 2001. The sale concerns six companies (in Germany, France, Switzerland, Netherlands, Italy and Spain), employing 224 persons, which are expected to make a turnover of EUR 60 million in 2000.